Woebot

Name: Woebot
Brand: Woebot

Woebot is a conversational, CBT-informed digital mental health platform that delivers structured exercises, mood check-ins, and safety screening through partner and research channels.

Est 2017|Valuation $230M|Raised $129.4M|21 Ref Customers

LinkedIn 19K|Web traffic 21K|FTEs 44|HQ San Francisco, California, US

Published Oct 12, 2026

01Common complaints

If you require an actively supported consumer app with self-serve sign-up: Woebot’s app retirement (June 30, 2025) makes it a poor fit.
If you require integrated human clinicians as the primary intervention: consider Talkspace, BetterHelp, or Lyra.
If you need crisis support tooling: Woebot is not positioned as a crisis service; formal protocols and alternative tools are required.
If you need transparent, predictable pricing without sales involvement: Wysa (teams) or consumer subscriptions like Headspace provide clearer entry costs.
If you require strong, independently validated long-term outcomes: the chatbot category has evidence limitations; terminated/withdrawn trial statuses should prompt deeper diligence.

- If you require an actively supported consumer app with self-serve sign-up: Woebot’s app retirement (June 30, 2025) makes it a poor fit. - If you require integrated human clinicians as the primary intervention: consider Talkspace, BetterHelp, or Lyra. - If you need crisis support tooling: Woebot is not positioned as a crisis service; formal protocols and alternative tools are required. - If you need transparent, predictable pricing without sales involvement: Wysa (teams) or consumer subscriptions like Headspace provide clearer entry costs. - If you require strong, independently validated long-term outcomes: the chatbot category has evidence limitations; terminated/withdrawn trial statuses should prompt deeper diligence.

Deal disqualifiers (poor fit)

Seeking a full replacement for therapy or psychiatric care
Requires an actively supported consumer app with self-serve sign-up
Requires transparent public pricing and self-serve procurement

Known limitations (vendor and market reality)

Not a crisis service (category-wide constraint; Woebot directs users to external resources).
App retirement and access limitations: The consumer app was retired (June 30, 2025) and accounts anonymized (July 31, 2025), which is a major limitation for broad public access.

Roadmap / future visibility

No detailed public roadmap was found in accessible official sources during this research. Enterprise buyers should request a roadmap and consider contractual commitments to service continuity and feature delivery.

Scale / reliability

Woebot historically operated at consumer scale based on app store signals and published usage figures. Enterprise-scale reliability metrics are not publicly verifiable; buyers should request uptime history, incident disclosures, and support SLAs.

Why some customers left / churn reasons

Product availability and access changes: users outside certain regions and others reported inability to create accounts or access the app as availability changed over time; the consumer app retirement is the primary churn driver.
Experience quality: some users report chatbots can feel limited or mismatched to personal nuance.

02Why they buy

Potential differentiators supported by available evidence

Vendor-stated compliance posture: The vendor reports HIPAA alignment and a SOC 2 Type 2 examination.
Responsible-AI approach: Woebot describes scripted, expert-crafted conversational flows rather than unrestricted generative models, with the intent of reducing risk of inaccurate outputs.
Concerning-language detection: NLP-based detection with redirection to external resources is implemented as a safety measure.

- **Vendor-stated compliance posture:** The vendor reports HIPAA alignment and a SOC 2 Type 2 examination. - **Responsible-AI approach:** Woebot describes scripted, expert-crafted conversational flows rather than unrestricted generative models, with the intent of reducing risk of inaccurate outputs. - **Concerning-language detection:** NLP-based detection with redirection to external resources is implemented as a safety measure.

Where competitors may have clearer advantages

Human care availability: BetterHelp, Talkspace, and Lyra provide clinician access.
Pricing transparency: Wysa and Headspace publish entry pricing.
Broader wellness content: Headspace and Calm maintain larger content libraries and general wellness framing.

Why customers chose Woebot (inferred from reviews)

Based on community and media discussion, reasons include:

Immediate access (24/7 availability)
Lower cost versus therapy (historical consumer access)
Anonymity and ease of initial use
Structured CBT techniques for reframing thoughts

03Field reports

Review platform coverage reality

Woebot is primarily a mental health app and digital therapeutic product, and it does not appear to have extensive coverage on mainstream B2B software review platforms (G2/Capterra) that provides procurement-focused buyer intelligence. Buyer feedback is therefore disproportionately visible on community sites and app store reviews rather than procurement-style platforms.

Positive sentiment (community)

From community posts, users describe Woebot as calming and useful in acute moments:

“As someone who struggles with extreme anxiety and depression, Woebot helps me see things from a different perspective and calms me down.” (community forum)
“When I’m in the thick of a depressive episode, I need help right away—but I can’t always see my therapist… This app has gotten me through so many bad episodes.” (community forum)
“I can’t believe Woebot is free and has no ads.” (community forum)

From a CBT-focused discussion thread, a user notes Woebot’s usability and specific CBT-style features:

“I liked Woebot it’s free. It didn’t teach me anything new but it’s cute and user friendly.” (community forum)

From community posts, users describe Woebot as calming and useful in acute moments: - “As someone who struggles with extreme anxiety and depression, Woebot helps me see things from a different perspective and calms me down.” (community forum) - “When I’m in the thick of a depressive episode, I need help right away—but I can’t always see my therapist… This app has gotten me through so many bad episodes.” (community forum) - “I can’t believe Woebot is free and has no ads.” (community forum) From a CBT-focused discussion thread, a user notes Woebot’s usability and specific CBT-style features: - “I liked Woebot it’s free. It didn’t teach me anything new but it’s cute and user friendly.” (community forum)

Negative / critical sentiment (community + independent blog)

Recurring criticisms include surface-level responses and limitations in conversational depth. Examples from independent reviews and community posts:

“Minimal responses… The illusion of being part of a conversation.”
Notifications/check-ins stopping
Replies that don’t align with user inputs
Underwhelming task recommendations and limited interventions

A broader media review of AI therapy chatbots reports mixed user reactions: some users described responses as forced and superficial, reflecting the common complaint that chatbots can feel impersonal.

Recurring criticisms include surface-level responses and limitations in conversational depth. Examples from independent reviews and community posts: - “Minimal responses… The illusion of being part of a conversation.” - Notifications/check-ins stopping - Replies that don’t align with user inputs - Underwhelming task recommendations and limited interventions A broader media review of AI therapy chatbots reports mixed user reactions: some users described responses as forced and superficial, reflecting the common complaint that chatbots can feel impersonal.

Vendor-published clinical development milestones

FDA Breakthrough Device Designation: Woebot announced that the FDA granted Breakthrough Device Designation to WB001, an investigational digital therapeutic for postpartum depression delivered over an 8-week program and intended as prescription-only under clinician supervision.
- Critical note: Breakthrough Device Designation is not the same as FDA clearance or approval; it indicates the FDA will prioritize interaction and review, but the product still must demonstrate safety and effectiveness.
Pivotal trial enrollment: Vendor announcements referenced enrollment activities for a multi-center, randomized, double-blind, controlled trial for WB001.
- Critical note: vendor press releases do not provide results; buyers should request published outcomes and full study documentation.

- **FDA Breakthrough Device Designation:** Woebot announced that the FDA granted Breakthrough Device Designation to WB001, an investigational digital therapeutic for postpartum depression delivered over an 8-week program and intended as prescription-only under clinician supervision. - Critical note: Breakthrough Device Designation is not the same as FDA clearance or approval; it indicates the FDA will prioritize interaction and review, but the product still must demonstrate safety and effectiveness. - **Pivotal trial enrollment:** Vendor announcements referenced enrollment activities for a multi-center, randomized, double-blind, controlled trial for WB001. - Critical note: vendor press releases do not provide results; buyers should request published outcomes and full study documentation.

External trial registry status (critical risk signal)

Clinical trial registry entries for postpartum depression studies involving WB001 show statuses that include terminated and withdrawn listings.

Critical interpretation: Terminated or withdrawn trials can occur for many reasons (enrollment issues, operational constraints, strategic pivots, safety signals, or efficacy signals). Public registry status alone does not explain the cause. Buyers should request a detailed explanation, including whether any safety issues emerged and what evidence remains supporting clinical claims.

Clinical trial registry entries for postpartum depression studies involving WB001 show statuses that include terminated and withdrawn listings. - Critical interpretation: Terminated or withdrawn trials can occur for many reasons (enrollment issues, operational constraints, strategic pivots, safety signals, or efficacy signals). Public registry status alone does not explain the cause. Buyers should request a detailed explanation, including whether any safety issues emerged and what evidence remains supporting clinical claims.

04Best fit

Company sizes

Mid-market to enterprise healthcare organizations (health systems, payers) and larger employers where scale matters.
Best fit is generally large organizations (500+ employees) for employer deployments and multi-clinic health systems for clinical deployments.

Industries / verticals

Healthcare providers (primary care, pediatrics, OB/GYN/postpartum programs)
Payers and managed care organizations
Employers with wellbeing benefits

Roles & personas

Decision makers: VP/Director of Behavioral Health, Chief Medical Officer, Chief Clinical Officer, Population Health leaders, Benefits leaders (HR), Procurement/Vendor Management.
Influencers: Security and compliance teams, legal, clinical governance committees.
End users: patients/members/employees; care managers; clinicians using it as an adjunct.

Pain points addressed

Access gaps (waitlists, limited clinician availability)
Need for 24/7 coping tools between appointments
Standardized CBT skill-building at scale

Qualification criteria (good fit)

Intended as a supplement to human care, not a replacement
Has clear crisis escalation pathways external to the product
Can support adoption and engagement campaigns
Requires and will validate HIPAA and SOC 2 alignment

05The pitch

What the product does (objective)

A critical product reality: Woebot retired its consumer app; new accounts cannot be created and prior consumer accounts are no longer accessible. Woebot states that account data was anonymized and that there was a deadline for transcript requests. This materially changes the product from a consumer-downloadable tool to something primarily accessed via partners and research programs.

Woebot is a conversational, CBT-informed digital mental health product from Woebot Health. Historically it was delivered as an AI-powered chatbot via a consumer mobile app (and earlier through messaging platforms) that guided users through structured, evidence-based exercises and mood check-ins. In parallel, Woebot Health positions the platform for healthcare and enterprise partnerships and for investigational prescription digital therapeutics such as the postpartum depression program WB001. A critical product reality: Woebot retired its consumer app; new accounts cannot be created and prior consumer accounts are no longer accessible. Woebot states that account data was anonymized and that there was a deadline for transcript requests. This materially changes the product from a consumer-downloadable tool to something primarily accessed via partners and research programs.

Target market & positioning

Historically (consumer): Individuals seeking self-guided mental health support for anxiety, depression, and stress, often as a supplement to therapy.
B2B / Clinical positioning: Health systems, payers, employers, and clinical programs seeking scalable, 24/7 adjunct behavioral health support; and investigational digital therapeutics (SaMD) for specific conditions such as postpartum depression.
Positioning: Emphasizes evidence-based methods, a responsible-AI approach, and privacy considerations; explicitly not a crisis service.

- **Historically (consumer):** Individuals seeking self-guided mental health support for anxiety, depression, and stress, often as a supplement to therapy. - **B2B / Clinical positioning:** Health systems, payers, employers, and clinical programs seeking scalable, 24/7 adjunct behavioral health support; and investigational digital therapeutics (SaMD) for specific conditions such as postpartum depression. - **Positioning:** Emphasizes evidence-based methods, a responsible-AI approach, and privacy considerations; explicitly not a crisis service.

Get a comprehensive analysis of Woebot including market position, competitive landscape, adoption trends, and peer benchmarks.

Download full report →